Systemic hypotension during the first postnatal week is associated with increased mortality and morbidity in the very low birth weight (VLBW) neonate. Hypotension is generally defined as blood pressure below the fifth percentile of the gestational-and postnatal-age dependent blood pressure norms. Recent studies indicate that in most VLBW neonates, cerebral blood flow autoregulation is indeed lost when blood pressure reaches the fifth percentile. Treatment of the circulatory compromise should address the primary pathogenic factor(s) of the condition (hypovolemia, myocardial compromise, failure of vasoregulation or a combination of factors). Recent findings also suggest that vasopressor resistance can be treated with a brief course of low-dose hydrocortisone. However, due to the short-and potential long-term side effects of early hydrocortisone treatment, its use should be restricted to neonates with vasopressor-resistant hypotension. Finally, concomitant administration of hydrocortisone with indomethacin should be avoided due to the increased incidence of gastrointestinal perforations.
Introduction
In the very low birth weight (VLBW) neonate, the relationship between systemic blood pressure and organ blood flow is complex, especially in the immediate postnatal period. Although some information is now available on these aspects of neonatal hemodynamics, their impact on mortality and morbidity is not well defined. This paper briefly discusses the available information on blood pressure and its relationship to organ blood flow in the VLBW neonate during the first postnatal week and reviews the pathogenesis of early neonatal shock and the treatment of vasopressor-resistant hypotension in this patient population.
Definition of hypotension and its relationship to low systemic perfusion Hypotension is defined as the blood pressure range where vital organ blood flow autoregulation is lost. If effective treatment is not initiated, blood pressure may further decrease and reach the 'ischemic threshold,' resulting in tissue ischemia and permanent organ damage. Neither the blood pressure causing loss of autoregulation nor the critical blood pressure resulting in direct tissue damage is known for the VLBW neonate in the immediate postnatal period. 1 Although the normal autoregulatory blood pressure range is not known, in clinical practice the lower limits of the 'normal' blood pressure range are usually defined as the blood pressure values below the fifth percentile of the gestational-and postnatal-age dependent blood pressure norms established for the VLBW neonatal patient population. During the first postnatal day, this number is generally considered to be equal to the numerical number of the given patient's gestational age. However, most [2] [3] [4] but not all 5 studies using 133 Xe clearance or near infrared spectroscopy (NIRS) to assess changes in cerebral blood flow (CBF) have found that the lower limit of the autoregulatory blood pressure range may be around 30 mm Hg even in the 1-day-old extremely low birth weight (ELBW) neonate. These findings are supported by observations made by the use of ultrasonography.
A confounding finding to the straightforward-appearing blood pressure-CBF relationship has been provided by a series of studies using superior vena cava (SVC) flow measurements to indirectly assess brain perfusion in the VLBW neonate with a focus on the ELBW infant in the immediate postnatal period. 7, 8 The findings of these studies suggest that, in the 1-day-old ELBW neonate, blood pressure in the normal range may not always guarantee normal vital organ (brain) blood flow. The reason for this finding is not known. However, by the second postnatal day, normal blood pressure is highly likely to be associated with normal brain and systemic blood flow. 8 Hypotension, low systemic blood flow and clinical outcomes Loss of autoregulation does not necessarily result in cerebral injury (intraventricular hemorrhage (IVH) and/or periventricular leukomalacia (PVL)) unless significant swings in systemic blood pressure occur 9 and/or hypotension reaches the ischemic threshold 4 ( Figure 1) . Indeed, several studies have found an association between hypotension [9] [10] [11] [12] and alterations in CBF [13] [14] [15] and central nervous system morbidity (IVH, PVL) and neurodevelopmental outcome. [16] [17] [18] However, it is important to note that, although data on an association between hypotension and/or abnormal CBF and short-and long-term central nervous system morbidity are abundant, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] very little data are available demonstrating a causative relationship among these factors.
Clinical presentations of hypotension and low systemic blood flow in the VLBW neonate during the first postnatal week Treatment of neonatal shock should be directed to address the primary underlying pathophysiology. Although it is often difficult to establish with certainty the primary etiology of neonatal shock (hypovolemia, cardiogenic, vasoregulatory or mixed), the clinical presentation itself may serve as a guide for the treatment of hypotension even in the absence of the ability to monitor cardiac output and organ blood flow at the bedside. The following frequently encountered clinical presentations of neonatal cardiovascular compromise occur in the VLBW neonate during the first postnatal week: (ii) peripheral vasodilation and hyperdynamic myocardial function primarily in VLBW neonates born to mothers with chorioamnionitis or (iii) perinatal depression with secondary myocardial dysfunction and/or abnormal peripheral vasoregulation.
2. From the second postnatal day during the first week: Hypotension and/or decreased systemic blood flow due to a hemodynamically significant patent ductus arteriosus (PDA). 3. Any time during the first week: Hypotension and/or decreased systemic blood flow due to (i) relative adrenal insufficiency and vasopressor/inotrope resistance, and/or (ii) specific systemic inflammatory response syndrome such as seen in cases with sepsis and/or necrotizing enterocolitis (NEC).
This paper will now briefly review the mechanisms of cardiovascular actions of the most frequently used vasopressors and inotropes (dopamine, epinephrine and dobutamine) and discuss the management of the hypotensive 1-day-old VLBW neonate presenting either with delayed myocardial adaptation or peripheral vasodilation. Finally, the management of the hypotensive VLBW neonate with relative adrenal insufficiency and vasopressor resistance will be addressed. The pathophysiology and management of the other typical clinical presentations of shock in the VLBW neonate have recently been reviewed elsewhere.
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Mechanisms of action of vasopressors and inotropes As detailed discussion of developmentally regulated mechanisms of action of the most frequently used vasopressors (dopamine and epinephrine) and inotrope (dobutamine) is beyond the scope of this paper, the reader is referred to reviews and original papers on this topic. [20] [21] [22] [23] Figures 2, 3, and 4 illustrate the dose-dependent cardiovascular and renal actions of dopamine, epinephrine and dobutamine in the neonatal patient population.
Hypotension and altered systemic blood flow in the VLBW neonate during the immediate postnatal period Transient myocardial dysfunction During the first postnatal day, VLBW neonates may present with shock because of the inability of the immature myocardium to pump against the increased peripheral vascular resistance following delivery. 25 In addition, while attempting to maintain adequate perfusion pressure, the immature neonate's vasoconstrictive vasoregulatory response may involve the cerebral vascular bed in addition to the vasoconstriction in the nonvital organs. 26 Although a significant number of these patients will also be hypotensive, in others blood pressure may remain within the normal range. 7, 8 Recognition of the latter presentation (normal blood pressure with decreased CBF) requires the ability for the Figure 1 The flat portion of the curve represents the autoregulatory plateau. The upper threshold is not known. Below the lower threshold, which is thought to be around 30 mm Hg, blood flow falls more in proportion to blood pressure. The critical closing pressure (CrCP) depends on arterial elasticity and intracranial pressure. The ischemic threshold is assumed to be around 50% of resting blood flow but the blood pressure at the ischemic threshold is not known. Adapted with permission, Early Human Development 4 .
bedside assessment of CBF using SVC flow measurements 7, 27 and/or NIRS. 3, 5, 9, 22 Management of this presentation of circulatory compromise is difficult and findings in the literature are somewhat contradictory. In a well-executed series using SVC blood flow as a surrogate measure of CBF in VLBW neonates during the first postnatal day, Evans, Kluckow, Osborn and colleagues described the hemodynamics of systemic and cerebral hypoperfusion, 7, 8 the relationship between recovery from hypoperfusion and the development of IVH, 8 the weak relationship between SVC blood flow and systemic blood pressure 8 and the association between neurodevelopmental outcome at 3 years of age and low SVC blood flow during the first 24 postnatal hours. 18 In addition, this group performed a randomized blinded clinical trial with a crossover Figure 2 In the preterm neonate, low doses of dopamine stimulate the dopaminergic receptors. At low-to-medium doses, effects of alpha-adrenergic receptor stimulation also appear. At medium-to-high doses (>8-10 mg/kg/min), effects of both beta-and alpha-receptor stimulation dominate the hemodynamic response to the drug. 21 However, this response is influenced by several factors (state of cardiovascular adrenergic receptor expression, etc) regulated by the level of maturity and disease severity. Figure 3 In the preterm neonate, at low-to medium doses of epinephrine administration, effects of beta-and alpha-adrenergic receptor stimulation become apparent. 22 The cardiovascular response is influenced by several factors (state of cardiovascular adrenergic receptor expression, etc) regulated by the level of maturity and disease severity. 1 design to compare the effects of dopamine and dobutamine at 10 and 20 mcg/kg/min on SVC flow and blood pressure in VLBW neonates during the first postnatal day. 27 They found that dopamine improved systemic blood pressure more effectively at the two doses used, while dobutamine was better at increasing SVC flow at the two doses tested. As pharmacodynamics rather than pharmacokinetics determine the cardiovascular response to these sympathomimetic amines, a limitation of this study is the lack of a stepwise titration of these drugs in search for the optimal hemodynamic response. Indeed, a recent study using continuous NIRS monitoring to assess the relative changes in CBF demonstrated that, by stepwise titration of dopamine and epinephrine, both drugs are equally effective in the low-tomoderate dose range at improving blood pressure and CBF in VLBW neonates during the first postnatal day. 22 Finally, recent findings using multiple, noncontinuous measurements of CBF by NIRS to assess the response of CBF and blood pressure to dopamine in ELBW neonates during the first two postnatal days also suggest that these patients respond to moderate-to-high doses of dopamine with an increase in both the blood pressure and CBF. 3 However, although CBF returns to the presumed normal range as blood pressure normalizes, its autoregulation remains impaired. Indeed, findings of an earlier study support this notion and indicate that, in sick preterm neonates, it may take up to 30-40 min or more for CBF autoregulation to recover after blood pressure has been normalized. 28 In summary, treatment of the hypotensive 1-day-old VLBW neonate remains complex even if systemic perfusion can be assessed by functional echocardiography. The use and stepwise titration of low-to-moderate dose dopamine 3, 6, 20, 22, 28 or epinephrine 22 to achieve blood pressure values 3 to 6 points higher than the gestational age of the patient is the preferred approach by many neonatologists during the first postnatal day. However, if there is evidence of myocardial dysfunction, dobutamine should be the first-line medication and low-dose dopamine may be added if blood pressure decreases upon initiation of dobutamine administration. However, one must bear in mind that in these cases, systemic vascular resistance should only be increased very carefully by dopamine as it may induce further decreases in the cardiac output secondary to the myocardial dysfunction. Finally, it is not known whether the use of dopamine, epinephrine or dobutamine as the first-line vasoactive agent in the treatment of the hypotensive 1-day-old VLBW neonate offers an advantage over the other drugs in improving mortality and short-and long-term morbidity.
Vasodilation and hyperdynamic myocardial function
Recent data indicate that VLBW neonates born after chorioamnionitis, especially if they also present with funisitis, develop hypotension in the presence of unchanged or increased cardiac output. 29 This presentation suggests that their systemic vascular resistance is low and these alterations in cardiovascular function correlate with cord blood interleukin-6 levels. 29 However, even in these patients, the presence of maternal fever or a neonatal immature-to-total white blood cell ratio over 0.4 may be associated with decreased left ventricular fractional shortening. These findings indicate that, in VLBW neonates born after chorioamnionitis, hypotension is primarily caused by vasodilation, although a variable degree of myocardial dysfunction may also contribute to the hemodynamic disturbance.
On the basis of these findings, treatment of hypotension in the 1-day-old VLBW neonate born after chorioamnionitis should be Figure 4 In the preterm neonate, dobutamine increases cardiac output and exerts a variable degree of a peripheral vasodilatory effect. 23, 24 The cardiovascular response is influenced by several factors (state of cardiovascular adrenergic receptor expression, etc) regulated by the level of maturity and disease severity. 1 tailored to address both components of the cardiovascular compromise (vasodilation and potential myocardial dysfunction). In these cases, dobutamine administration alone may lead to further decreases in systemic vascular resistance, especially in patients with increased cardiac output and little or no myocardial compromise. Therefore, in these patients, carefully titrated low-to-moderate doses of dopamine (or epinephrine) will likely be effective. However, one should bear in mind that, at higher doses, dopamine or epinephrine may increase systemic vascular resistance to levels where cardiac output becomes compromised and, despite improving blood pressure, systemic blood flow may decrease. Thus, if functional echocardiography is not available, the indirect measures of tissue perfusion (urine output, capillary refilling time, base deficit and/or serum lactate levels) should be carefully followed to monitor for the state of organ blood flow and vasopressor support should be adjusted accordingly.
Treatment of VLBW neonates with vasopressor resistant shock More than 50% of hypotensive VLBW infants requiring dopamine at doses >10 mg/kg/min during the immediate postnatal period cannot be weaned off the drug for well over 3 to 4 days and many develop vasopressor-resistant hypotension. 1, 20, 30, 31 These patients with vasopressor dependence or vasopressor-resistant hypotension respond to relatively low doses of hydrocortisone with an improvement in blood pressure and urine output, and frequently wean off vasopressor support within 24-72 h. 1, 20, [30] [31] [32] [33] Factors that may explain the corticosteroid responsiveness of vasopressorresistant hypotension in these neonates include the downregulation of cardiovascular adrenergic receptors in critical illness 33 and the development of relative adrenal insufficiency. 30, 31, 34 The attenuated cardiovascular responsiveness to catecholamines in critical illness is, at least in part, caused by the downregulation of the cardiovascular adrenergic and type-1 angiotensin-2 receptors and their intracellular signaling systems. 31, 33, 35 As expression of these receptors and their signaling systems is inducible by corticosteroids, 36 steroid administration has the potential to reverse adrenergic receptor downregulation. In addition, corticosteroids inhibit prostacyclin production and the induction of nitric oxide synthase, 37 and thus limit the pathological vasodilation associated with the nonspecific or specific inflammatory response of the critically ill neonate. In addition to these genomic effects, corticosteroids exert certain nongenomic actions, 38 resulting in a rapid increase in the sensitivity of the cardiovascular system to catecholamines. 33, 38 Relative adrenal insufficiency, especially in the VLBW neonate, is the other factor contributing both to the increased incidence of vasopressor resistance and the enhanced responsiveness to hydrocortisone in this patient population. 34 In the VLBW neonate, relative adrenal insufficiency is thought to contribute to the disruption of the balance between adrenergic receptor destruction and synthesis, resulting in decreased sensitivity of the cardiovascular system to endogenous and exogenous catecholamines. Therefore, steroid administration especially in the hypotensive ELBW neonate may also be considered as a hormone replacement therapy. 33, 34 Although the effects of low-dose hydrocortisone on blood pressure, urine output and vasopressor requirement have been more extensively studied, [31] [32] [33] only preliminary data are available on other aspects of the hemodynamic response (cardiac output, systemic vascular resistance and organ blood flow) to low-dose hydrocortisone. The understanding of the hydrocortisone-associated changes in these hemodynamic parameters is important because hydrocortisone, at least in theory, may increase blood pressure at the expense of systemic perfusion by primarily enhancing the peripheral vasoconstrictive effects of vasopressors. However, recent preliminary findings suggest that hydrocortisone improves all aspects of cardiovascular function including cardiac output and organ blood flow. 39 Potential side effects of hydrocortisone administration are numerous, 33 but the increase in gastrointestinal perforations when the drug is concomitantly administered with indomethacin is the most important and clinically relevant acute side effect. This severe complication should limit the use of hydrocortisone to VLBW neonates not receiving indomethacin unless it is used as a last resort in indomethacin-exposed VLBW neonates with intractable hypotension. It is important to note that hydrocortisone administration without indomethacin treatment does not appear to increase the incidence of isolated gastrointestinal perforations. 40 Finally, although high-dose and prolonged hydrocortisone exposure after the first postnatal weak does not appear to affect long-term neurodevelopment, 41 there are no data available on the long-term effects of early low-dose hydrocortisone on brain development. Therefore, until data on long-term neurodevelopment of low-dose and early hydrocortisone treatment become available, hydrocortisone should be used carefully in the immediate postnatal period in the VLBW neonate and its use should be restricted to cases with vasopressor resistance.
